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ABSTRACT
Oncolytic viruses that selectively replicate in tumor cells can be used for 
treatment of cancer. Accumulating data suggests that virus induced oncolysis can 
enhance anti-tumor immunity and break immune tolerance. To capitalize on the 
immunogenic nature of oncolysis, we generated a quadruple modified oncolytic 
adenovirus expressing granulocyte-macrophage colony-stimulating factor (GMCSF). 
Ad5/3-E2F-Δ24-GMCSF (CGTG-602) was engineered to contain a tumor specific 
E2F1 promoter driving an E1 gene deleted at the retinoblastoma protein binding site 
(“Δ24”). The fiber features a knob from serotype 3 for enhanced gene delivery to 
tumor cells. The virus was tested preclinically in vitro and in vivo and then 13 patients 
with solid tumors refractory to standard therapies were treated. Treatments were 
well tolerated and frequent tumor- and adenovirus-specific T-cell immune responses 
were seen. Overall, with regard to tumor marker or radiological responses, signs of 
antitumor efficacy were seen in 9/12 evaluable patients (75%). The radiological 
disease control rate with positron emission tomography was 83% while the response 
rate (including minor responses) was 50%. Tumor biopsies indicated accumulation 
of immunological cells, especially T-cells, to tumors after treatment. RNA expression 
analyses of tumors indicated immunological activation and metabolic changes 
secondary to virus replication.
INTRODUCTION
Despite progress in cancer prevention, early 
diagnosis and conventional treatment methods, most 
metastatic solid tumors remain essentially incurable. One 
experimental treatment option is oncolytic virotherapy 
which utilizes the potential many viruses have for 
replication in tumor cells, followed by lysis. Adenoviruses 
are the most extensively utilized viruses for gene therapy 
approaches, and with their well demonstrated safety in 
thousands of patients, and several positive randomized 
trials [1–4], they remain a solid platform for innovative 
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therapy approaches. In the field of oncolytic viruses, two 
randomized trials have been completed, both with positive 
results. An oncolytic adenovirus improved the efficacy of 
chemotherapy for treatment of metastatic head and neck 
cancer [5] and a GMCSF armed oncolytic herpes viruses 
was effective in the treatment of metastatic melanoma 
[6]. However, overall survival results have not yet been 
positive on a statistically significant level and thus room 
for improvement remains.
Adenoviruses are immunogenic viruses [7], and since 
it seems that the immune response is a major determinant 
of the antitumor effect of oncolytic viruses [8, 9], they have 
a great potential for cancer therapy utilities. Based on the 
“danger signal” paradigm [10], the presence of oncolytic 
viruses within a tumor can act as a provocative danger signal 
for the immune system. Further, tumor associated antigens 
(TAAs) are released by oncolysis for presentation to the 
immune system in an environment conducive for immunity 
[11–13]. Arming adenovirus with immunostimulatory 
molecules has been utilized as an approach to further 
augment immune responses against tumor antigens.
The design of the novel oncolytic virus Ad5/3-E2F-
Δ24-GMCSF incorporates three concepts.
I) Serotype 3 knob for enhanced entry into tumor 
cells. Most clinical trials performed with adenoviruses 
thus far are based on serotype 5 or the closely related 
serotype 2 [4]. The primary receptor for these viruses is 
the coxsackie adenovirus receptor (CAR) [14] which is 
often down-regulated in aggressive human tumors [15]. 
Enhanced delivery to and killing of cancer cells, clinical 
specimens and xenograft tumors in mice is achieved 
when the native Ad5 fiber knob is replaced by that of 
serotype 3 virus, without loss of safety in humans [16, 17]. 
Supporting the safety of Ad3 components, a completely 
serotype 3 based oncolytic adenoviruses have shown 
potential in preclinical [18] and clinical settings [19].
II) E2F1 promoter and Δ24 deletion of viral E1A for 
efficient and specific replication in tumor cells. Although 
previous constructs such as CGTG-101 [9], CGTG-102 [16] 
and CGTG-103 [20], featuring a single “delta-24” mutation 
for tumor selectivity, have been safe in patients, there 
may be advantage for multiple levels of control. Tumor 
selectivity with “delta-24” occurs after E1A expression, and 
thus E1A is expressed even in normal cells. E1A can cause 
toxicity and it may contribute to anti-viral immunity, and 
there may be some “leaky” activation of late viral proteins, 
again possibly resulting in toxicity or anti-viral immunity. 
Thus, it would be appealing to control expression of the 
mutated E1A with a tumor specific promoter [21]. The 
human E2F1 promoter is active in most tumor cell lines 
mutated in the pRb pathway [22, 23] thus facilitating the 
use of the E2F1 promoter in most if not all tumors [24, 25].
III) Granulocyte macrophage colony-stimulating 
factor (GMCSF) is a widely used immunostimulatory 
molecule in oncolytic viruses in clinical settings, now 
also proven effective in a randomized, global phase 3 
melanoma trial which met its primary endpoint of durable 
response rate [6, 26]. It is a potent inducer of systemic 
anti-tumor immunity associated with recruitment and 
maturation of antigen presenting cells (APCs), mainly 
dendritic cells, as well as recruitment of cells of the 
innate immunity arm, including natural killer cells and 
neutrophils. In immunocompetent Syrian hamsters virally 
produced GMCSF has been able to activate anti-tumor 
immune responses, enhancing the efficacy of oncolytic 
adenovirus [9, 27], and human data is compatible with 
these notion [9, 16, 20, 28]. An advantage of local 
production of cytokines is that high concentrations 
can be achieved where useful (at the tumor site) while 
retaining lower systemic levels, which can cause adverse 
events or untoward immunological consequences such as 
recruitment of myeloid derived suppressor cells [16, 29].
RESULTS
Preclinical experiments
The E1A region, E3 region and fiber are genetically 
modified in Ad5/3-E2F-Δ24-GMCSF (Figure 1A). Virally 
produced GMCSF was tested functional by analyzing 
the growth of GMCSF dependent TF-1 erythroleukemia 
cells upon addition of filtered supernatant from Ad5/3-
E2F-Δ24-GMCSF infected A549 cells (Figure 1B top). 
The selectivity of Ad5/3-E2F-Δ24-GMCSF was 
studied in primary human hepatocytes. The levels of 
infective viral particles remained 15 to 11 fold lower 
than with the parental oncolytic control virus without the 
E2F1 promoter (replication controlled only by the 24bp 
deletion) and 65 to 19 times lower than in wild type Ad5 
infected hepatocytes at 48 and 72 hours, respectively 
(Figure 1B middle).
To study the selectivity of viral replication in 
Syrian hamsters, a model reported semipermissive for 
human adenovirus [16], tumors and livers were collected 
following virus injection and analyzed for virus copy 
number (Figure 1B bottom). A secondary peak seen in 
virus copy number in tumors suggests effective virus DNA 
replication, while particles remained low in the liver at all 
time points, suggesting lack of replication in normal cells.
The in vitro efficacy of Ad5/3-E2F-Δ24-GMCSF was 
evaluated on three cancer cell lines representing non-small 
cell lung, ovarian and prostate cancer (Figure 1C). Ad5/3-
E2F-Δ24-GMCSF achieved cancer cell killing efficacy 
comparable to the isogenic control without the E2F1 
promoter and wild type Ad5, while being superior to the 
non-replicative Ad5/3luc1 (P < 0.05), which implies retained 
oncolytic potency despite quadruple genetic modification.
In vivo potency and selectivity of Ad5/3-E2F-Δ24-
GMCSF was characterized in an immunocompetent Syrian 
hamster model previously reported semi -permissive for 
adenoviral replication [30, 31]. Subcutaneous hamster 
pancreatic cancer (HapT1) tumors were treated with 
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Figure 1: (A) A schematic representation of the Ad5/3-E2F-Δ24-GMCSF virus. The E1A promoter is replaced by a 
human E2F1 promoter, which controls the transcription of the E1A gene. The E1A gene features a 24 base-pair deletion to avoid the 
self-activation of the promoter by E2F released by E1A-Rb interaction, a critical fault in previous designs with an intact E1A gene. 
Gp19k and 6.7K in E3 have been replaced with the cDNA of human GM-CSF. The serotype 5 (Ad5) fiber knob has been replaced 
by the serotype 3 (Ad3) knob. (B) Top panel: Ad5/3-E2F-Δ24-GMCSF -expressed GMCSF is functionally active. TF1 cells, which 
require human GMCSF for viability, were cultured in the presence of human recombinant GMCSF or filtered supernatant from 
virus infected cells. As a control, supernatant from cells infected with a virus not expressing GM-CSF was used (Ad5/3-Δ24). The 
viability of TF1-cells treated with growth medium (GM) only was set as 100% hGMCSF control and filtered supernatant showed 
significantly (P < 0.001) higher viability over GM, while no difference was seen between other groups. Middle panel: Less infective 
virus particles were produced by Ad5/3-E2F-Δ24-GMCSF in human primary hepatocytes at 48 and 72 h time points compared to 
the control viruses, indicating low replication in normal human cells. Bottom panel: to evaluate tumor selectivity of the virus, livers 
of non-tumor-bearing Syrian hamsters were injected and no viral E4 copy number increase was detected with qPCR. In contrast, 
E4 copy number increased in HapT-1 tumors. Replacing the native E1A promoter with the E2F-1 promoter does not impair virus 
replication and cell killing effect in vitro (C) or in vivo (D). (C) Results of a cell viability assay shows the cell killing efficiency of 
Ad5/3-E2F-Δ24-GMCSF compared to Ad5/3-Δ24-GMCSF - a control virus bearing the genetically intact E1A promoter - a wild 
type serotype 5 virus and a non-replicating control virus Ad5/3luc1 in A549 lung cancer cells, SKOV3ip.1 ovarian cancer cells and 
PC3-MM2 prostate cancer cells. (D) Ad5/3-E2F-Δ24-GMCSF significantly (P < 0.01) slowed down tumor progression compared to 
the mock (growth medium only) animals in Syrian Hamsters bearing pancreatic cancer tumors. 3 × 108 VP of virus was administered 
intratumorally on days 0, 3 and 6. Concomitant low dose cyclophosphamide did not significantly improve the anti-tumor effect of 
Ad5/3-E2F-Δ24-GMCSF.
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intratumoral injections (Figure 1D) and Ad5/3-E2F-Δ24-
GMCSF restricted tumor progression significantly when 
compared to cyclophosphamide only or to mock (growth 
medium only) treated groups. The recent discovery that 
not all hamster tumor cell lines are fully permissive to 5/3 
chimeric virus – in comparison to human substrates – may 
have impacted efficacy in this experiment [32]. To evaluate 
the ability of Ad5/3-E2F-Δ24-GMCSF to cause oncolysis of 
HapT1 cells, a cell killing assay was performed. Interestingly, 
and in contrast to many other hamster cell lines [28], 
HapT1 did not allow for productive oncolysis (Figure S1) 
and therefore the anti-tumor effect was caused by immune 
response towards tumor cells filled with virus components 
(virus DNA replicated) and surrounded by GMCSF.
Patients
Thirteen patients with advanced metastatic tumors 
refractory to and progressing after standard therapy were 
treated with 2–4 rounds of Ad5/3-E2F-Δ24-GMCSF 
(Table 1). Treatments were performed in a personalized 
manner and 1–10 tumor sites were injected. Patient C332 
received only 1 round of treatment and then underwent 
pre-planned surgery. Most patients had received multiple 
lines of chemotherapy before virus treatments and 
were progressing, thus constituting a highly treatment 
refractory patient population (Table S1). There was 
variation between tumors and patients, and thus the 
patient population well represents “real-life” patients with 
advanced cancer [33–35].
Safety of the treatments
Table S2 summarizes the adverse reactions 
recorded during all 39 treatment rounds. Grade 1–2 flu 
like symptoms, fever, fatigue and pain were experienced 
in more than half of the treatments. Most grade 3 events 
were self-limiting or treatable as outpatient, and no grade 
4 or 5 adverse effects were observed.
Virus replication
All patients evaluated for the presence of Ad5/3-
E2F-Δ24-GMCSF in serum were negative prior to therapy 
(N = 11, Table 2). One day after the first treatment 8/13 
patients had measurable virus genomes, with the highest 
titer being 1141 VP/ml. 2/4 patients sampled on days 
3–8 were positive, with the highest titer of 11523 VP/ml 
serum, and both (O340 and H344) showed an increase in 
titer after day 1, suggestive of virus replication.
Typically, titers less than 500 VP/ml were seen 1 
day after the second and third treatments while no virus 
Table 1: Patients at baseline
Patient ID Age (y) Sex Diagnosis WHO Virus Dose** Treatment rounds
O314 62 F Ovarian cancer 1 1–3 × 1011 3
O337 69 F Ovarian cancer 2 5 × 1011 3
O340 74 F Ovarian cancer 0 5 × 1011 3
O351 72 F Ovarian cancer 2 3 × 1011 3
C312 54 M Rectum cancer 1 1–3 × 1011 3
C332* 49 F Colon cancer 0 8 × 1011 1
H192 54 M Pancreatic cancer 1 3 × 10
11 2
H344 58 F Pancreatic cancer 1 8 × 10
11 3
I347 51 M Melanoma 2 5 × 1011 3
R319 67 F Breast cancer 1 3–5 × 1011 3
R342 54 F Breast cancer 2 3 × 1011 2
R356 40 F Breast cancer 1 1 × 1012 4
S352 59 F Sarcoma 1 3–10 × 1011 3
S354 50 F Fibrosarcoma 2 3 × 1011 4
*Hyperthermic intraperitoneal chemotherapy (HIPEC) surgery 3 weeks later, thus included only for immunohistochemistry 
analysis. 
**First treatment was given at the lower indicated dose. All patients (excluding C332) received low dose cyclophosphamide 
to reduce T-reg cells, patients H192, H344, I347, S352 and S354 received also low dose pulse temozolomide to enhance 
autophagy resulting from oncolysis.
Oncotarget4471www.impactjournals.com/oncotarget
(N = 21) was seen on other days after the second and third 
treatments. These data are compatible with replication 
of the virus in tumors, especially subsequent to the first 
injection, with less release of genomes into the circulation 
occurring after 2nd and 3rd injection.
Neutralizing antibodies and anti-hexon 
antibodies
At baseline, 4 patients had a low titer (1–64) of anti-
Ad5/3 neutralizing antibodies (Table 2). 4 patients had an 
intermediate titer (256) while 2 patients had a high titer 
(4096) already at baseline. Thus, at baseline the median 
titer was 256 and by the time of the second treatment the 
titer had risen (P < 0.01) to a median of 4096 and stayed 
there until the end of follow-up.
To provide an alternative view on anti-viral 
antibodies, we also analyzed patient serums for anti-
hexon IgG, hexon being the main capsid protein of 
the virus. At baseline, all patient serums had low titers 
(between 30 and 200U/ml) of anti-hexon IgG. Three 
weeks after the first treatment all patients showed 
Table 2: Responses, survival and amounts of virus and neutralizing antibodies










after 1st after 2nd after 3rd
0 1 3–8 0 1 3–8 0 1 3–10 14–55
O314 Virus 0 0 0 < 500 0 0 0 mPR 71
NAb 1 1024
O337 Virus 0 < 500 0 0 < 500 mSD 276
O340 Virus 0 1141 3608 0 < 500 0 0 < 500 0 0 MMR (–10%) mCR 890
Nab 4096 4096
O351 Virus 0 0 < 500 0 0 0 0 mMR 87
NAb 256 4096
C312 Virus 0 < 500 0 < 500 < 500 SMD (+23%) mPD 397
Nab 4096 4096
H192 Virus 0 0 0 < 500 mPD 80
Nab 256 4096
H344 Virus 0 < 500 11523 0 < 500 0 0 < 500 0 0 PMD mPD 133
Nab 256 4096
I347 Virus 0 < 500 0 0 < 500 0 0 < 500 106
Nab 64 4096
R319 Virus 0 0 0 0 0 0 < 500 PMR (–49%) mPR 332
R342 Virus 0 < 500 < 500 mPD 76
R356 Virus 0 < 500 < 500 876 < 500 mPR 102
NAb 1 1024
S352 Virus 0 0 0 < 500 0 0 0 0 SMD (+6%) 112
NAb 16 1024
S354 Virus 0 789 0 0 < 500 0 CMR (–76%)a 1009*
NAb 256 4096 4096
MMR = minor metabolic response, SMD = stable metabolic disease, PMD = progressive metabolic disease, PMR = partial 
metabolic response, CMR = complete metabolic response.
acomplete metabolic response, 76% reduction in tumor size *patient alive on 14.1.2014 mPR = marker partial response, mSD = 
marker stable disease, mCR = marker complete response, mMR=marker minor response, mPD=marker progressive disease.
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increase in serum antibody titers (titers between 200 and 
3000). Titers stayed elevated with a slow decreasing trend 
in some patients, during the months following treatment 
(Figure S2A). Further, ascites samples from patient 
O314 were analyzed for anti-hexon antibody titers at 
baseline and 3 weeks after treatment and antibody levels 
increased from 57 U/ml to 509 U/ml (Figure S2B). Titers 
of antibodies attached to ascites cells were also evaluated, 
and they increased from 42 to 471 U/100 mg protein. 
The latter may indicate virus replication, and subsequent 
antibody binding to cells present in ascites, a typical 
location of ovarian cancer cells.
PET CT and tumor markers
All patients had progressing tumors prior to 
treatment. 6 patients could be assessed with PET-CT 
(modified PERCIST criteria [36]) (Table 2). Response 
was typically assessed 3–4 weeks after the last virus 
injection; typically 3 injections were given 3 weeks 
apart. R319 had partial metabolic response (PMR, 
49% reduction in metabolic activity) in the injected 
liver tumor and a complete metabolic response in a 
non-injected mediastinal tumor (Figure 4a), S354 had 
a complete metabolic response (CMR, Figure 4b and 
Figure S3), O340 had a minor metabolic response 
(MMR), C312 and S352 had stable metabolic disease 
(SMD) and H344 had progressive metabolic disease 
(PMD). Therefore, the radiological disease control 
rate (stable disease or better) was 83% while the PET 
response rate (including MMR) was 50%.
With regard to tumor markers, assessed for patients 
who had elevated markers at baseline, 3/10 patients had 
reduction of marker levels (O314, O337, O351), 2/10 
had initial reduction and subsequent elevation of marker 
levels (R356, R319), 1 patient had initial elevation and 
subsequent reduction (O340) and 4/10 had elevation of 
marker levels (H344, C312, R342, H192, Figure S4). 
Thus, overall, 6/10 patients had some indication of 
possible treatment benefits, as measured by tumor markers 
in serum. R319, O340, H344 and C312 were evaluated 
also with PET-CT. While R319 and O340 had partial and 
minor metabolic responses, C312 had only stabilization 
(and in fact a 23% increase in SUVmax, fulfilling criteria 
of SMD) and H344 had metabolic progression. Thus, there 
was rather good correlation between PET response and 
tumor marker data.
Overall, with regard to tumor marker or radiological 
responses, signs of antitumor efficacy were seen in 9/12 
evaluable patients (75%). These patients lived a median of 
135 days while the median survival of the other three was 
80 days. In patient I347 treatment efficacy could not be 
evaluated with any method. Thus, in an overall intent-to-
treat analysis, there was some evidence of efficacy in 9/13 
patients (69%). Overall survival of all patients is shown 
in (Figure S5).
Changes in peripheral blood T-cell activity are 
seen in patients treated with Ad5/3-E2F-Δ24-
GMCSF
Peripheral blood mononuclear cells (PBMCs) were 
collected and pulsed with Ad5 penton peptide or with 
tumor associated peptide pools (Survivin, CEA + NY-
ESO-1 or c-myc + SSX2). IFN-γ production was then 
analyzed with ELISPOT to evaluate the number of anti-
tumor and anti-viral T-cells (Figure 2). Interestingly, in 
most patients the behavior of anti-tumor cells closely 
resembled changes seen in anti-viral cells; if the latter 
increased, also the former did and vice versa. In 8 patients 
(R319, O314, C312, I347, O337, R356, H344, S352), 
there was an increase (considered as a higher than at 
baseline at any timepoint) in one or more classes of anti-
tumor T-cells, while in 3 patients (O340, O351, S354) 
there was a decrease. For anti-viral T-cells, the respective 
numbers were also 8 and 3 (increase: R319, O314, C312, 
I347, O337, R356, O340, H344, decrease: O351, S352, 
S354) and thus there was concordance in 9/11 (82%) 
patients between anti-tumor T-cells and anti-viral T-cells 
(the discordant patients were O340 and S352). This 
finding may suggest that in humans, anti-viral response 
corresponds and may contribute to anti-tumor response 
through epitope spreading and reduction of tumor-
associated immunological tolerance. [17] However, as 
proposed before [17, 37], there was no correlation between 
changes in T-cells and clinical indicators of treatment 
efficacy, as a decrease of T-cells in blood might indicate 
trafficking to tumors [17, 38]. T-cell anergy [38] (no 
induction, no trafficking) was not seen in any patients.
Antibodies against tumor associated antigens 
decrease in responding patients
Antibodies against tumor associated antigens are 
frequently elevated in cancer patients even at early stages 
of the disease, indicating recognition of tumor epitopes 
by the immune system [39]. Interestingly, a body of 
data from the cancer vaccine field indicates that anti-
tumor antibodies can be indicative of treatment efficacy. 
Specifically, a decrease in anti-tumor antibodies can 
indicate anti-tumor response and an increase can indicate 
lack of response [40]. For example, antibodies against 
NY-ESO-1 were shown to disappear from serum of 
patients that are in remission [41].
In our patients, antibodies against CEA, NY-ESO-1, 
survivin or MUC-1 frequently decreased in patients with 
signs of anti-tumor efficacy (Figure 3A). For example, 
patient O314 seemed to benefit from treatment as she 
had a partial response in CA12–5. She had a decrease 
in all four anti-tumor antibodies measured in her blood. 
R319 had a partial metabolic response in PET and a 
partial tumor marker response, and decrease in 3/4 anti-
tumor antibodies in her blood. R356 had a partial marker 
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response and a decrease in all three anti-tumor antibodies. 
Likewise, there seemed to be correlation between clinical 
benefits and anti-tumor antibodies in C312 and O351. In 
contrast, in patients H192 and H344, there were no signs 
of clinical benefits, and in both cases anti-tumor antibodies 
increased. Overall, a significant (P = 0.02) correlation 
between anti-tumor antibodies and clinical signs of benefit 
from treatment was seen.
In one case (O314), anti-tumor antibody levels in 
blood could be compared to anti-tumor antibody levels 
in ascites and cells present in ascites (which typically 
contains tumor cells). Interestingly, there was close 
correlation between all three compartments, suggesting 
that systemic measurement of antibody levels could be a 
reliable indicator of local events at the tumor (Figure 3B), 
which is compatible with the long half-life and systemic 
dissemination of antibodies in general.
Biopsies
Patient C322 underwent surgery 3 weeks after 
treatment with Ad5/3-E2F-Δ24-GMCSF, which allowed 
immunohistochemical analysis of the operated tumor. 
More CD8+ cytotoxic T-cells (brown) were seen in tumor 
than in normal tissue (Figure 4c).
Biopsies before the first virus treatment and three 
weeks after the third virus treatment were available from 
patients O340 and R356 (Figure 4d). Before treatment 
both of the core needle biopsies taken from patient 
O340 and R356 showed only tumor tissue. In contrast, 
after treatment biopsies showed only a proportion of 
tumor tissue (O340 circa 15%, R356 circa 75% tumor 
cells). Assuming similar skills by the radiologist on both 
occasions, one explanation for this finding would be 
treatment mediated anti-tumor effects.
Immunohistochemical stainings for various 
immunological cell types were performed (Figure 4d). 
Interestingly with patient O340 a clear increase in the 
proportion of mature T-cells (CD3) (x34), T-helper 
cells (CD4) (x9) and cytotoxic T-cells (CD8) (x26) is 
seen, while CD11c-positive cells, B-cells (CD19) and 
CD25-positive cells (including eg. regulatory T-cells) 
virtually disappeared from the tumor. Concurrently the 
number of monocytic macrophages (CD68 and CD163) 
increased (x10 and x8 respectively). This patient seemed 
to respond to treatment as measured by PET-CT (MMR), 
markers (mCR), long survival (890d) (Table 2) and 
decrease in anti-Ca15–3 antibodies (Figure 3). Moreover, 
a drastic decrease in tumor antigen specific T-cells was 
observed in blood preceding the biopsy (Figure 2). As 
proposed [17], a decrease in anti-tumor T-cells in blood 
is compatible with trafficking of those cells to the tumor, 
a notion supported by evidence in this case, as CD8+ cells 
increased 26-fold in the tumor.
Less dramatic changes in cell density were also 
seen in the immunohistochemical stainings of patient 
Figure 2: Ad5/3-E2F-Δ24-GMCSF elicited T cell responses against adenovirus and tumor epitopes in cancer 
patients. PBMCs harvested from patients treated with Ad5/3-E2F-Δ24-GMCSF were analyzed by IFN-gamma ELISPOT upon stimulation 
with a mix of peptide from Adenovirus 5 and mixes of peptides from tumor antigens CEA and NY-ESO-1 (pool1), c-myc and SSX2 (pool2) 
and Survivin alone. Bars represent the frequency of IFN-gamma producing peptide specific PBMCs per million cells. SFC, Spot Forming 
Colonies.
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Figure 3: (A) Antibodies against tumor associated antigens (TAAs) NY-ESO-1, CA-15–3, CEA and survivin were 
analyzed from patient serum (A) and ascites fluid and cells of patient O314 (B) before and after viral treatment, and 
the data is presented as proportional change (%) of antibody levels (as estimated by ELISA absorbance units) from 
pre-treatment values. (A) Treatment often resulted in decrease of elevated levels of antibodies against TAAs in patients that showed 
a concomitant response in PET-CT or decrease in marker levels (patients O314, R356, R319, O340, C312, O351). Patients H192 and 
H344 did not show any benefit in PET-CT or markers and increasing levels of antibodies against TAAs were noted. (B) Malignant ascites 
(resulting from peritoneal tumor masses) was removed from the peritoneal cavity of patient O314 before and 19 and 40 days after virus 
administration. As with the serum samples decreasing amounts of antibodies against TAA were noted.
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R356 (up to x3). A partial response (mPR) in markers 
was observed but the patient survived only 102 days 
(Table 2). Some changes were seen in blood T-cells and 
anti-tumor antibodies (Figure 2–3). Taken together, the 
data suggest that in this patient the anti-tumor effect was 
transient, perhaps chiefly mediated by oncolysis, since a 
clear immunological change did not occur at the tumor, as 
estimated by immunohistochemistry of the biopsy.
In these two cases with biopsy material available, 
we also analysed RNA expression patterns and predicted 
underlying biological functions by using Ingenuity 
pathway analysis software (Ingenuity System Inc, USA) 
(Figure S6). Thousands of pathways were analyzed, but 
only 25 (O340) and 18 (R356) were found significantly 
altered by treatment. Interestingly, nine of these pathways 
were the same in both patients, possibly hinting at 
mechanism of action. Noteworthy were the three retinoid 
X receptor (RXR) pathways, with known associations 
to immunology, particularly CD8+ and regulatory T-cell 
responses [42, 43]. These and “acute phase response 
signaling” pathways seem to suggest that treatment with 
Ad5/3-E2F-Δ24-GMCSF induces immunological activity.
Figure 4: Positron emission tomography-computed tomography (PET-CT) fusion images from patients R319 
(a) and S354 (b). (a) A non-injected mediastinal lesion disappeared after treatment (white arrows). 49% reduction in metabolic 
activity of an injected lesion in the liver (black arrow). (b) A total of 76% reduction is seen in tumor (stars) volume of patient 
S354. A 46% reduction in tumor volume was seen at 3 months, 76% reduction at 6 months and a stable situation at 9 months after 
the first treatment. Patient S354 was given 3 treatments every 3 weeks and after that a continuation treatment scheme was started 
with treatments given every 3 weeks. (c) Patient C322 was operated 3 weeks after treatment with Ad5/3-E2F-Δ24-GMCSF. More 
CD8+ cytotoxic T-cells (brown) were seen in tumor (right panel) than normal tissue (left panel) collected during the operation. 
(d) Biopsies before the first virus treatment and three weeks after the third virus treatment were available from patients O340 and 
R356. Immunohistochemical CD8 staining (dark brown dots) is shown. The area of the tumor was drawn by a pathologist and 
marked by a dotted line in the figure. Amount of stained cells in the tumor area divided by the area containing tumor is shown in 
the graph below. Large amounts of immunological cells seem to arrive to the tumor after the treatment. Also large quantities are 
seen around the tumor rim. Especially profound is the T-cell infiltration within the tumor of patient O340 that had a lower quantity 
of immunological cells at baseline.
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DISCUSSION
Based on the preclinical and clinical findings 
reported here, Ad5/3-E2F-Δ24-GMCSF seems to 
function as designed: The Ad3 fiber knob enables efficient 
transduction of tumor cells while the E2F1 promoter and 
24bp deletion provide excellent tumor selectivity (as 
demonstrated by lack of replication in hamster livers in 
vivo and human hepatocytes ex vivo). Functional GMCSF 
is produced following cellular entry.
Interestingly, as reported before with this HapT1 
Syrian hamster tumor model with a similar although 
distinct virus [16] it seems that after the virus has entered 
the tumor it takes 3–4 days for the viral DNA copy number 
to peak after which a much lower amount of virus DNA 
is present in the tumor, probably because infected cells 
were killed either due to oncolysis or immunological 
eradication of infected cells. Seemingly in support of the 
former, the amount of viral DNA again starts to increase 
after dipping, which is compatible with a second wave of 
viral replication (Figure 1B bottom). However, lack of 
productive oncolysis in vitro with this cell line (Figure S1) 
suggests in fact that in vivo killing of cells filled with virus 
genomes and other components is in fact immunological. 
Our conclusions are that a) Ad5/3 is not oncolytic on 
Syrian hamster HapT1 cells in vitro (although the virus 
is oncolytic in some other Syrian hamster cell lines [28]), 
b) DNA replication is nevertheless seen in vivo, c) in vivo 
efficacy is caused mostly by immune response against the 
virus and/or stimulated by GMCSF. It seems unlikely that 
the virus would be oncolytic in vivo but not in vitro and 
thus we believe the qPCR result merely indicates DNA 
replication, not productive oncolysis, thus pin-pointing 
the block in permissivity between genome replication 
and lysis of the cell. The waves of DNA replication 
seen by qPCR must therefore reflect GMCSF stimulated 
immunological clearance of cells with a high content of 
adenoviral components.
While the design of this virus might facilitate 
intravenous administration we have not found a good 
animal model to test this. Syrian hamsters are technically 
challenging (fur, thick skin, lacking tail veins) with 
regard to an intravenous route and mouse tissues are non-
permissive for human adenovirus [44]. Variance in cell 
killing with serotype 5 wild type compared to our fiber 
modified 5/3 virus in different cell lines (Figure 1C) might 
be due to the relative expression of the main Ad5 receptor 
coxsackie and adenovirus receptor versus the presence of 
Ad3 receptors such as desmoglein 2 as published [45–47]. 
Treatments were safe and many patients with 
variable types of solid cancers refractory to other therapies 
seemed to show signs of efficacy when evaluated by PET-
CT or by tumor markers. PET-CT was chosen as the 
imaging method as we believe the immune reaction caused 
by treatment results in tumor swelling which restricts the 
utility of size based evaluation criteria [36].
No virus DNA was detected in blood after the 2nd 
and 3rd injections, suggesting tight restriction of oncolysis 
to the tumors, or less replication than after the 1st cycle, 
or both. Interestingly, as reported with preclinical data 
[28] we noted disappearance of a non-injected tumor with 
patient R319 (Figure 4a). These findings are in support of 
the immunogenic mechanism being more important than 
pure oncolysis with regard to efficacy.
The patents had quite advanced tumors and they 
were heavily pretreated often with multiple lines of 
chemotherapy. Thus, when oncolytic virus treatment was 
stopped, some patients progressed rapidly, while some 
stabilized for extended times. It should be noted that 
most patients progressed off therapy, and thus eventual 
progression is not really evidence of lack of efficacy. 
However, as this was not a randomized trial we would 
hesitate to make any assumptions on efficacy over 
control patients. There are many well-known caveats in 
comparisons to historical controls and thus we believe 
a randomized setting is the appropriate approach for 
assessing effects on overall survival.
Interestingly, PET-CT and tumor marker responses 
and survival (Table 2) seemed to correlate with: 1) changes 
in the numbers and activity of circulating tumor reactive 
lymphocytes (Figure 2); 2) a decrease in anti-tumor 
antibodies in blood and ascites (Figure 3); 3) increases in 
CD3, CD4, CD8, CD68 and CD163 positive cells at the 
tumor (Figure 4).
Although these preliminary findings need to be 
confirmed in larger patient cohorts, immunohistochemical 
analysis of tumor biopsies suggested that immunological 
cells accumulated at tumors in patients responding to 
treatment while at the same time changes in cancer 
specific T cells in blood could be seen. This is compatible 
with previously published data and suggestive of 
trafficking of anti-tumor (and anti-viral) cells from blood 
into tumors [17, 46, 48–51]. Viral DNA was often detected 
in serum for several days after the first treatment while 
after subsequent treatments qPCR tended to be negative. 
Antibody titer against the virus increased exponentially 
while antibodies against tumor associated antigens 
decreased in responding patients, a finding proposed 
associated with anti-tumor efficacy [40, 41].
At baseline patient R356 had more (CD3 x33, 
CD4 x10, CD8 x9, CD11c x21, CD68 x15, CD163 x12) 
immunological cells in the tumor than patient O340 
(Figure 4). After treatment the number of immunological 
cells increased more with O340 than with R356. Since 
both tumors were progressing at baseline, the data 
might indicate that the tumor of R356 featured stronger 
local immunosuppression (regulatory T cells etc.) to 
counterbalance the more prominent immunological 
infiltrate. For such patients virus induced immunological 
response might not be as useful, as the “gas pedal” 
is already fully engaged. For such tumors, “releasing 
the brake” might be more useful instead, alone or in 
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combination with oncolytic immunotherapy. Thus new 
drugs such as PD-1 or anti-CTLA-4 antibodies combined 
to oncolytic viroterapy and/or T-cell therapy might lead to 
additive efficacy. It is clear that more patients are needed 
to study these phenomena in more detail and no definite 
conclusions can be made from a small number of biopsies, 
but on the other hand the data reported here may be the 
first available information on potentially important aspects 
of the technology.
In summary, Ad5/3-E2F-Δ24-GMCSF (CGTG-602) 
seems safe and effective for treatment of cancer. Clinical 
trials would be useful for demonstrating these aspects in 
more homogeneous patient populations, and for collecting 
more biological samples, to extend upon the preliminary 
analyses done here.
MATERIALS AND METHODS
Viruses and cancer cell lines
The construction of Ad5/3-E2F-Δ24-GMCSF 
is described in supplementary materials and methods. 
Ad5/3-Δ24, Ad5/3lucI and Ad5/3-D24-GM-CSF have 
been described [16, 46, 52]. Cell lines used herein and 
their testing have been described [18, 53].
Preclinical experiments
In vitro assays. GMCSF dependent TF-1 
erythroleukemia cells (Sigma Aldrich, St Louis, MO) 
were used to evaluate the functionality of GMCSF as 
described [16]. The results constitute of an average of 
7 (mock 21, hGMCSF 11) samples, students T-test was 
used for statistics. The experiment showed that virus-
produced hGMCSF was as bioactive as the commercial 
positive control (Recombinant human GM-CSF, 2ng/ml, 
PeproTech, 300–03) as reported [9, 28, 53–56]. Oncolytic 
potency was tested with MTS-assay performed 6 days 
(A549 and PC3-MM2) or 14 days (SKOV3.ip1) after virus 
incubation when 100% cell killing with the highest viral 
dose was observed [18]. Shown results are the average 
of four samples, error bars represent standard deviation. 
Students T-test was used for statistical analyses. Selectivity 
of virus replication in human primary hepatocytes is 
described in supplementary materials and methods. In vivo 
efficacy. Hamster pancreatic cancer tumors (HapT1) were 
grown subcutaneously in Syrian hamsters as described [9]. 
At 7 days tumors were injected with 3 × 108 VP/tumor of 
either of Ad5/3-E2F-Δ24-GMCSF (n = 6) or Ad5/3-Δ24-
GMCSF (n = 5) 3 times every 3 days. Further, 5 animals 
received cyclophosphamide intraperitoneally (2 mg/
hamster) in combination with Ad5/3-E2F-Δ24-GMCSF, 
5 hamsters received cyclophosphamide only and 4 animals 
were mock-treated with intratumoral growth medium 
injections. Tumor volume was calculated by using a 
formula of (0.5 × length) × (width2).
In vivo tumor selectivity of Ad5/3-E2F-Δ24-
GMCSF replication. After hamster HapT1 tumors reached 
approximately 0,5 cm in diameter (7 days), 3 × 108 VP 
of Ad5/3-E2F-Δ24-GMCSF was injected intratumorally 
(n = 8 tumors/timepoint). Hamsters without tumors (n = 2 
hamsters/timepoint) were injected directly into the liver. 
Animals were killed and tumors or livers collected 0.5, 
24, 48, 72 or 96 hours after virus injection, snap-frozen 
and stored at –80°C. Quantitative PCR has been described 
[16]. Activity of human GM-CSF in Syrian hamsters has 
been described previously [9, 28, 53–56].
Patient treatments
Patients were treated in an Advanced Therapy 
Access Program, regulated by EC/1394/2007 on advanced 
therapy medicinal products, amending Directive 2001/83/
EC and Regulation (EC) No 726/2004. According to 
EC/1394/2007 manufacturing of advanced therapy 
medicinal products shall be authorized by the competent 
authority of the Member State, which in Finland is the 
Finnish Medical Agency (FIMEA). FIMEA also requires 
reporting of adverse reactions. Virus administration was 
performed by ultrasound-guided intratumoral injection and 
circa one fifth of the dose was given intravenously during 
the first treatment only. The rationale for the latter relates 
to the generally low to average amount of neutralizing 
antibodies that are typically present at baseline, while 
after treatment antibodies often increase rapidly and thus 
the value of subsequent intravenous dosing is unknown. 
In any case, there is no need for subsequent intravenous 
injection because the tumor produces virus which is then 
shed into blood. Thus in subsequent injections the whole 
dose was given intratumorally. Most patients were treated 
three times every three weeks. Doses of 1–10 × 1011 VP 
were used based on safety results previously published 
with Ad5/3-Δ24-GMCSF, a related virus lacking the 
E2F1 promoter [57]. All patients exluding C332 received 
low dose cyclophosphamid for reduction of regulatory 
T-cells [58]. Patients H192, 344, I347, S352 and S354 
received also low dose temozolomide for enhancement 
of autophagy during oncolysis [59]. Typically, 
cyclophosphamide was used throughout the treatments 
with a dose of 50mg/day while temozolomide was used 
5–7 days before and/or 7–14 days after the treatment at 
100mg/day. Neither approach is known to have anti-tumor 
activity on their own [37, 60]. Written informed consent 
was obtained from all patients. Patients were monitored 
overnight at the clinic and then as outpatients for 28 days 
for adverse events. Adverse reactions were recorded 
according to Common Terminology for Adverse Events 
v3.0. Survival and late adverse events were followed 
ad infinitum. ATAP treatments are not a trial but an 
individualized treatment program. However, in a separate 
research project, collection and analysis of biopsies was 
approved by the HUCH operative ethics committee, and 
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a separate informed consent procedure was employed 
to ensure separation of research from treatment (Dnro 
368/13/03/02/2009). Other patient sample analyses 
are also approved by the local Ethics Committee (HUS 
62/13/03/02/2013). Because many cancer patients have 
symptoms due to disease, preexisting symptoms were 
not scored if they did not become worse. However, if the 
symptom became more severe, e.g., pretreatment grade 1 
changed to grade 2 after treatment, it was scored as grade 2. 
The neutralizing antibody assay [61] and the determination 
of virus genomes in blood [16] are previously published. 
Interferon gamma ELISPOT is described [17], all results 
were compared to cells spontaneously producing the 
cytokine, i.e. PBMCs without stimulation. For detail on 
the immunohistocehmical stainings, tumor biopsies and 
their quantitation please refer to supplementary materials 
and methods.
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